Pfizer and BioNTech’s Covid-19 vaccine candidate shows promising efficacy

This article was originally published here

The interim analysis showed that BNT162b2 vaccine candidate is over 90% effective in preventing Covid-19 in participants without evidence of prior SARS-CoV-2 infection. BioNTech co-founder and CEO Ugur

The post Pfizer and BioNTech’s Covid-19 vaccine candidate shows promising efficacy appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply